(Nasdaq: TLSA) Makes Red To Green Move Heading Into Power Hour

*Sponsored Just Announced! Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is Our Next Potential Breakout Idea… Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) Comes Backed By Several Potential Catalysts Like: Neurodegenerative Market to Double: Projected to grow from $52B in 2024 to over $102B by 2034, fueling demand for treatments like Foralumab. Bullish Momentum: Tiziana Life Sciences (Nasdaq: TLSA) triggered 17 Bullish Signals on TradingView yesterday afternoon. Game-Changing Intranasal Therapy: Foralumab is the only fully human anti-CD3 monoclonal antibody delivered intranasally for precision treatment. SPMS Trials Expand: Yale, Johns Hopkins, and Cornell join Phase 2 trials, enhancing Foralumab's credibility in secondary progressive multiple sclerosis research. Alzheimer’s Breakthrough: First patient with moderate Alzheimer’s dosed at Brigham and Women’s Hospital, addressing a critical unmet need. Featured in Nature Reviews Neurology: Foralumab recognized for its potential in conditions like multiple sclerosis, Alzheimer’s, ALS, and Parkinson’s. Beyond Neurodegeneration: Nasal anti-CD3 therapy shows promise in tackling metabolic challenges tied to GLP-1 agonist discontinuation. Keep reading to see why (TLSA) is topping our watchlist right now… January 23, 2025 Dear Reader, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is now triggering 18 Bullish Signals on TradingView’s technical analysis tool using the 15 minute time-frame. Including the Momentum Indicator. This morning, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) announced it will not engage in immediate capital raising activities, reflecting confidence in its fiscal and research stability.  This follows yesterday’s breakthrough revelation of new immune biomarkers in MS patients treated with nasal Foralumab.  The study, utilizing advanced RNA sequencing, identified changes in Tregs, memory T cells, and monocytes, all linked to immune regulation and reduced brain inflammation.  Supported by clinical imaging data, these findings were praised by leading researchers as a pivotal step toward personalized MS treatments.  Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) remains at the forefront of innovation in neurodegenerative disease therapies. Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) isn’t just imagining this future—they’re building it. As a clinical-stage biopharmaceutical company, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is developing breakthrough therapies using transformational dr-ug delivery technologies that could redefine how we approach immunotherapy. Their efforts come at a pivotal moment. The global neurodegenerative disease market is forecasted to grow from $52B in 2024 to over $102B by 2034, driven by an aging population, advancements in precision medicine, and a growing need for effective therapies to combat conditions like Alzheimer’s, Parkinson’s, and multiple sclerosis.  And according to Benzinga, insiders own over 72% of the company’s shares—what do they know? Could it be the groundbreaking potential of their intranasal therapy, the rapidly growing neurodegenerative disease market, or the promising results from their recent clinical trials? Tiziana Life Sciences, Ltd. (Nasdaq: TLSA)’s focus on intranasal Foralumab places it in a strong position to address these urgent and rapidly expanding needs. At the forefront of their pipeline is intranasal foralumab, the only fully human anti-CD3 monoclonal antibody currently in clinical development.  With the potential to improve efficacy, safety, and tolerability compared to traditional intravenous treatments, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is turning heads for all the right reasons. Let’s explore what sets this company apart. Recent Developments Promising Results for Metabolic Disorders Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) announced findings that its nasal anti-CD3 therapy mitigates side effects commonly associated with GLP-1 agonist discontinuation, such as muscle loss and bone density issues. This development highlights the potential of nasal anti-CD3 in sustaining tissue homeostasis and improving patient outcomes in metabolic and age-related diseases. Foralumab Featured in Nature Reviews Neurology A review article published in Nature Reviews Neurology highlighted Foralumab’s therapeutic potential across multiple neurodegenerative diseases, including Alzheimer’s, multiple sclerosis, ALS, and Parkinson’s. The publication underscored the role of intranasal delivery in dampening microglial activation—a critical factor in disease progression. Alzheimer’s Clinical Trial Milestone Achieved The company dosed its first patient with moderate Alzheimer’s disease using intranasal Foralumab at Brigham and Women’s Hospital in Boston. This innovative therapy targets neuroinflammation by modulating microglial cells, a novel approach distinct from amyloid and tau protein-focused therapies. Expansion of SPMS Clinical Trial to Prestigious Institutions Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) recently expanded its Phase 2 clinical trial for non-active secondary progressive multiple sclerosis (SPMS) to include leading U.S. medical institutions such as Yale University, Johns Hopkins University, and Cornell University. The expanded trial reflects Tiziana’s commitment to advancing research in SPMS, a condition with no FDA-approved therapeutic options. The use of a centralized PET imaging site ensures data consistency and robust trial outcomes. These updates showcase Tiziana Life Sciences, Ltd. (Nasdaq: TLSA)’s relentless focus on addressing significant unmet medical needs with groundbreaking solutions. Redefining Treatment with Intranasal Foralumab At the heart of Tiziana’s efforts is Foralumab, the only fully human anti-CD3 monoclonal antibody currently in clinical trials. Administered intranasally, this therapy doesn’t just break the mold—it demolishes it. This innovative delivery system allows Foralumab to modulate the immune system efficiently while crossing the blood-brain barrier to target neuroinflammation directly. The potential benefits span multiple conditions: Secondary Progressive Multiple Sclerosis (SPMS): Characterized by a progressive loss of neurological function, SPMS remains one of the most challenging forms of multiple sclerosis to address. Alzheimer’s Disease (AD): By modulating microglial activity—key drivers of neuroinflammation—Foralumab offers a fresh approach distinct from conventional amyloid-targeting treatments. The Focus on Neuroinflammatory and Neurodegenerative Conditions Tiziana has zeroed in on areas with substantial clinical challenges. Here’s a closer look at why its work matters: SPMS Progress: In an expanded access program, participants demonstrated improved fatigue levels and reduced brain inflammation, as measured by microglial activation. These are significant outcomes in a condition where effective therapies are limited. Alzheimer’s Disease: Preclinical studies have shown Foralumab’s ability to alleviate inflammation in the brain. With Phase 2 trials beginning in 2024, the therapy is positioned to offer a novel approach that complements existing treatments. What Sets Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) Apart A Unique Approach to Delivery: By choosing an intranasal delivery method, Tiziana ensures precise targeting of neuroinflammation with minimal systemic side effects. This is a pivotal advantage in managing chronic neurological conditions. Robust Data Supporting Its Platform: Published findings in the Proceedings of the National Academy of Sciences underscore Foralumab’s impact across multiple conditions, including SPMS and a recent global pan-demic. These results highlight its ability to regulate T-cell activity and reduce inflammation effectively. Experienced Leadership Driving Innovation: With Executive Chairman and Founder Gabriele Cerrone at the helm, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) benefits from a leadership team with deep expertise in dr-ug development. Cerrone’s history of guiding biotech firms to major milestones reinforces confidence in Tiziana’s trajectory. Potential Beyond the Current Pipeline: While SPMS and Alzheimer’s are the primary focuses, Foralumab’s mechanism of action points to broader applications across inflammatory and neurodegenerative diseases, setting the stage for further advancements. Key Milestones to Watch SPMS Phase 2a Progress: Ongoing trials are evaluating Foralumab’s efficacy and safety, with early data showing promising outcomes in reducing inflammation and improving symptoms. Alzheimer’s Phase 2 Launch: This trial will explore the therapy’s effects on microglial activity, a significant contributor to disease progression in Alzheimer’s. Expanded Research: Tiziana continues to explore additional indications where its intranasal anti-CD3 platform can make a meaningful difference. A Company Worth Watching Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is positioning itself as a leader in innovative therapies for neuroinflammatory and neurodegenerative diseases.  With groundbreaking science, proven leadership, and a clear focus on addressing critical medical challenges, this is a company making real strides in areas where effective solutions are desperately needed.  Tiziana Life Sciences, Ltd. (Nasdaq: TLSA)’s work stands as a testament to what’s possible when science and ingenuity converge. 7 Reasons Why Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) Jumped Onto Our Watchlist This Afternoon… 1. Rapidly Growing Market: The global neurodegenerative disease market is projected to expand from $52B in 2024 to over $102B by 2034, highlighting the need for innovative treatments like Foralumab. 2. Bullish Indicators: Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) triggered 17 Bullish Signals on TradingView’s technical analysis tool yesterday afternoon, which could reflect a growing interest in the company. 3. Innovative Intranasal Delivery: Tiziana Life Sciences, Ltd. (Nasdaq: TLSA)’s Foralumab stands out as the only fully human anti-CD3 monoclonal antibody delivered intranasally, offering a unique approach to addressing complex conditions with precision. 4. Expanded SPMS Clinical Trials: Prestigious institutions such as Yale, Johns Hopkins, and Cornell have joined the Phase 2 trials for secondary progressive multiple sclerosis (SPMS), amplifying the credibility of Foralumab’s potential impact. 5. Progress in Alzheimer’s Disease Research: The first patient with moderate Alzheimer’s disease was successfully dosed at Brigham and Women’s Hospital, advancing efforts to address a critical unmet need. 6. Recognized in a Leading Scientific Journal: Foralumab was featured in Nature Reviews Neurology, showcasing its relevance across conditions like multiple sclerosis, Alzheimer’s, ALS, and Parkinson’s. 7. Applications Beyond Neurodegeneration: Research shows that nasal anti-CD3 therapy may address challenges in metabolic conditions, such as those associated with GLP-1 agonist discontinuation. With its innovative intranasal delivery system, expanded clinical trials, and recognition from top institutions, Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) is making waves in a market poised to exceed $102B.  Consider adding (TLSA) to your watchlist—it could be one to follow closely. Keep a look out for my next update. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and Sica Media LLC, TD Media LLC has been hired for a period beginning on 01/23/2025 and ending on 01/23/2025 to publicly disseminate information about (TLSA:US) via digital communications. Under this agreement, we have been paid fifteen thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither TD Media LLC or its member owns shares of (TLSA:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/tlsa/#details

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice